-
1
-
-
84938746812
-
Continuous versus intermittent chemotherapy strategies in metastatic colorectal cancer: a systemic review and meta-analysis
-
Berry SR, Cosby R, Asmis TR, et al. Continuous versus intermittent chemotherapy strategies in metastatic colorectal cancer: a systemic review and meta-analysis. Ann Oncol 2015, 26:477-485.
-
(2015)
Ann Oncol
, vol.26
, pp. 477-485
-
-
Berry, S.R.1
Cosby, R.2
Asmis, T.R.3
-
2
-
-
33644843853
-
OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer-a Gercor study
-
Tournigand C, Cervantes A, Figer A, et al. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer-a Gercor study. J Clin Oncol 2006, 24:394-400.
-
(2006)
J Clin Oncol
, vol.24
, pp. 394-400
-
-
Tournigand, C.1
Cervantes, A.2
Figer, A.3
-
3
-
-
73349089651
-
Can chemotherapy be discontinued in unresectable metastatic cancer? The GERCOR OPTIMOX2 study
-
Chibaudel B, Maindrault-Goebel F, Lledo G, et al. Can chemotherapy be discontinued in unresectable metastatic cancer? The GERCOR OPTIMOX2 study. J Clin Oncol 2009, 27:5727-5733.
-
(2009)
J Clin Oncol
, vol.27
, pp. 5727-5733
-
-
Chibaudel, B.1
Maindrault-Goebel, F.2
Lledo, G.3
-
4
-
-
42949149159
-
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study
-
Saltz LB, Clarke S, Diaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J ClinOncol 2008, 26:2013-2019.
-
(2008)
J ClinOncol
, vol.26
, pp. 2013-2019
-
-
Saltz, L.B.1
Clarke, S.2
Diaz-Rubio, E.3
-
5
-
-
80755155711
-
Alternative end points to evaluate a therapeutic strategy in advanced colorectal cancer: evaluation of progression-free survival, duration of disease control, and time to failure of strategy-an aide et Recherche en Cancérologie Digestive Group study
-
Chibaudel B, Bonnetain F, Shi Q, et al. Alternative end points to evaluate a therapeutic strategy in advanced colorectal cancer: evaluation of progression-free survival, duration of disease control, and time to failure of strategy-an aide et Recherche en Cancérologie Digestive Group study. J Clin Oncol 2011, 29:4199-4204.
-
(2011)
J Clin Oncol
, vol.29
, pp. 4199-4204
-
-
Chibaudel, B.1
Bonnetain, F.2
Shi, Q.3
-
6
-
-
84929514070
-
Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group
-
Simkens LHJ, van Tinteren H, May AM, et al. Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group. Lancet 2015, 385:1843-1852.
-
(2015)
Lancet
, vol.385
, pp. 1843-1852
-
-
Simkens, L.H.J.1
van Tinteren, H.2
May, A.M.3
-
7
-
-
84954025962
-
Quality of life (QoL) in patients with metastatic colorectal cancer (MCRC) receiving maintenance therapy after first-line inductive treatment: a QoL sub-analysis of the AIO KRK 0207 phase III trial
-
(abstr)
-
Quidde J, Arnold D, Hegewisch-Becker S, et al. Quality of life (QoL) in patients with metastatic colorectal cancer (MCRC) receiving maintenance therapy after first-line inductive treatment: a QoL sub-analysis of the AIO KRK 0207 phase III trial. Ann Oncol 2014, 25:522P. (abstr).
-
(2014)
Ann Oncol
, vol.25
, pp. 522P
-
-
Quidde, J.1
Arnold, D.2
Hegewisch-Becker, S.3
-
8
-
-
84908573757
-
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase3 trial
-
Heinemann V, Fischer von Weikersthal L, Decker T, et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase3 trial. Lancet Oncol 2014, 15:1065-1075.
-
(2014)
Lancet Oncol
, vol.15
, pp. 1065-1075
-
-
Heinemann, V.1
Fischer von Weikersthal, L.2
Decker, T.3
-
9
-
-
84937204003
-
CALBG/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with expanded ras analyses untreated metastatic adenocarcinoma of the colon or rectum (mCRC)
-
(abstr)
-
Lenz H, Niedzwiecki D, Innocenti F, et al. CALBG/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with expanded ras analyses untreated metastatic adenocarcinoma of the colon or rectum (mCRC). Ann Oncol 2014, 25:501O. (abstr).
-
(2014)
Ann Oncol
, vol.25
, pp. 501O
-
-
Lenz, H.1
Niedzwiecki, D.2
Innocenti, F.3
-
10
-
-
84911474269
-
Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow up
-
Van Cutsem E, Cervantes A, Nordlinger B, et al. Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow up. Ann Oncol 2014, 25:iii1-iii9.
-
(2014)
Ann Oncol
, vol.25
, pp. iii1-iii9
-
-
Van Cutsem, E.1
Cervantes, A.2
Nordlinger, B.3
-
11
-
-
84926475781
-
Bevacizumab continuation versus no continuation after first-line chemo-bevacizumab therapy in patients with metastatic colorectal cancer: a randomized phase III non-inferiority trial (SAKK 41/06)
-
Koeberle D, Betticher DC, Von Moos R, et al. Bevacizumab continuation versus no continuation after first-line chemo-bevacizumab therapy in patients with metastatic colorectal cancer: a randomized phase III non-inferiority trial (SAKK 41/06). Ann Oncol 2015, 26:709-714.
-
(2015)
Ann Oncol
, vol.26
, pp. 709-714
-
-
Koeberle, D.1
Betticher, D.C.2
Von Moos, R.3
-
12
-
-
84883339111
-
A randomized phase III trial on maintenance treatment with bevacizumab alone or in combination with erlotinib after chemotherapy and bevacizumab in metastatic colorectal cancer: the Nordic ACT trial
-
Johnsson A, Hagman H, Frödin J-E, et al. A randomized phase III trial on maintenance treatment with bevacizumab alone or in combination with erlotinib after chemotherapy and bevacizumab in metastatic colorectal cancer: the Nordic ACT trial. Ann Oncol 2013, 24:2335-2341.
-
(2013)
Ann Oncol
, vol.24
, pp. 2335-2341
-
-
Johnsson, A.1
Hagman, H.2
Frödin, J.-E.3
-
13
-
-
84954029886
-
Bevacizumab with or without erlotinib as maintenance therapy in patients with metastatic colorectal cancer (GERCOR DREAM; OPTIMOX3): a randomised, open-label, phase 3 trial
-
(in press).
-
Tournigand C, Chibaudel B, Samson B, et al. Bevacizumab with or without erlotinib as maintenance therapy in patients with metastatic colorectal cancer (GERCOR DREAM; OPTIMOX3): a randomised, open-label, phase 3 trial. Lancet Oncol 2015, (in press).
-
(2015)
Lancet Oncol
-
-
Tournigand, C.1
Chibaudel, B.2
Samson, B.3
-
14
-
-
84954026292
-
Immunomodulary maintenance therapy with TLR-9 agonist MGN 1703 in patients with metastatic colorectal carcinoma-the randomized phase 3 IMPALA study
-
(abstr).
-
Arnold D, Zurlo A, Salazar R, et al. Immunomodulary maintenance therapy with TLR-9 agonist MGN 1703 in patients with metastatic colorectal carcinoma-the randomized phase 3 IMPALA study. Ann Oncol 2014, 25:1077. (abstr).
-
(2014)
Ann Oncol
, vol.25
, pp. 1077
-
-
Arnold, D.1
Zurlo, A.2
Salazar, R.3
-
15
-
-
84856304557
-
First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase III MACRO TTD study
-
Diaz-Rubio E, Gomez-Espana A, Massuti B, et al. First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase III MACRO TTD study. Oncologist 2012, 17:15-25.
-
(2012)
Oncologist
, vol.17
, pp. 15-25
-
-
Diaz-Rubio, E.1
Gomez-Espana, A.2
Massuti, B.3
-
16
-
-
84892147161
-
Bevacizumab and capecitabine as maintenance therapy after initial bevacizumab+XELOX treatment in previously untreated patients with metastatic colorectal cancer: Phase III stop and go study result-a Turkish Oncology Group trial
-
Yalcin S, Uslu R, Dane F, et al. Bevacizumab and capecitabine as maintenance therapy after initial bevacizumab+XELOX treatment in previously untreated patients with metastatic colorectal cancer: Phase III stop and go study result-a Turkish Oncology Group trial. Oncology 2013, 85:328-335.
-
(2013)
Oncology
, vol.85
, pp. 328-335
-
-
Yalcin, S.1
Uslu, R.2
Dane, F.3
-
17
-
-
2542561964
-
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
-
Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004, 350:2335-2342.
-
(2004)
N Engl J Med
, vol.350
, pp. 2335-2342
-
-
Hurwitz, H.1
Fehrenbacher, L.2
Novotny, W.3
-
18
-
-
84884700039
-
Bevacizumab plus capecutabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial
-
Cunningham D, Lang I, Marcuello E, et al. Bevacizumab plus capecutabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial. Lancet Oncol 2013, 11:1077-1085.
-
(2013)
Lancet Oncol
, vol.11
, pp. 1077-1085
-
-
Cunningham, D.1
Lang, I.2
Marcuello, E.3
-
19
-
-
77955497309
-
Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study
-
Tebbutt NC, Wilson K, Gebski VJ, et al. Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study. J Clin Oncol 2010, 28:3191-3198.
-
(2010)
J Clin Oncol
, vol.28
, pp. 3191-3198
-
-
Tebbutt, N.C.1
Wilson, K.2
Gebski, V.J.3
|